Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
Airbus Joins Air India A320 Altitude Drop Probe 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
US Judge Dismisses Gautam Adani Criminal Charges 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Johnson & Johnson is reportedly exploring the acquisition of biopharmaceutical company Intra-Cellular Therapies, according to Bloomberg News. The potential deal, valued at approximately $10 billion, could be finalized as early as this week, though discussions remain in early stages.
Intra-Cellular Therapies is renowned for Caplyta, its FDA-approved treatment for schizophrenia and bipolar disorders. Acquiring the company would bolster J&J’s neuroscience portfolio, helping mitigate revenue declines expected from upcoming patent expirations on its blockbuster drugs.
Despite the promising prospects, sources caution that negotiations may not result in a finalized agreement. Intra-Cellular’s stock surged nearly 15% last Friday, reflecting heightened investor optimism over the potential acquisition.
J&J continues to focus on high-growth therapeutic areas to strengthen its pharmaceutical division amidst growing market competition. If successful, this acquisition would align with the company's strategy to expand its innovative treatments and sustain long-term growth.
